Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors

Gomperts, Edward D. ; Astermark, Jan LU ; Gringeri, Alessandro and Teitel, Jerome (2008) In Blood Reviews 22(Suppl 1). p.1-11
Abstract
Two bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven (R)). Both products are highly effective in controlling bleeding in the presence of inhibitory alloantibodies, yet their hemostatic efficacy can be unpredictable. As the results of the FEIBA NovoSeven (R) Comparative (FENOC) study illustrate, patients may respond better to one bypassing agent than the other. Furthermore, guidelines from an expert panel reflect that responsiveness to bypassing therapy may change from one bleed to the next in the same patient and even from hour to hour during the course of a single bleeding... (More)
Two bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven (R)). Both products are highly effective in controlling bleeding in the presence of inhibitory alloantibodies, yet their hemostatic efficacy can be unpredictable. As the results of the FEIBA NovoSeven (R) Comparative (FENOC) study illustrate, patients may respond better to one bypassing agent than the other. Furthermore, guidelines from an expert panel reflect that responsiveness to bypassing therapy may change from one bleed to the next in the same patient and even from hour to hour during the course of a single bleeding event. These findings underscore the need to have both bypassing products available to treat bleeding episodes in inhibitor patients, to frequently evaluate the efficacy of hemostasis during the course of a bleeding event, and to switch products early if the response to treatment is unsatisfactory. (C) 2008 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
discordant pairs, hemophilia, inhibitors, FEIBA, NovoSeven
in
Blood Reviews
volume
22
issue
Suppl 1
pages
1 - 11
publisher
Churchill Livingstone
external identifiers
  • wos:000254821800001
  • scopus:43449121545
ISSN
1532-1681
DOI
10.1016/S0268-960X(08)70001-8
language
English
LU publication?
yes
id
9a77c0b9-9bd5-4f53-80b1-fe37d5701db2 (old id 1207352)
date added to LUP
2016-04-01 12:08:48
date last changed
2022-03-13 05:55:48
@article{9a77c0b9-9bd5-4f53-80b1-fe37d5701db2,
  abstract     = {{Two bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven (R)). Both products are highly effective in controlling bleeding in the presence of inhibitory alloantibodies, yet their hemostatic efficacy can be unpredictable. As the results of the FEIBA NovoSeven (R) Comparative (FENOC) study illustrate, patients may respond better to one bypassing agent than the other. Furthermore, guidelines from an expert panel reflect that responsiveness to bypassing therapy may change from one bleed to the next in the same patient and even from hour to hour during the course of a single bleeding event. These findings underscore the need to have both bypassing products available to treat bleeding episodes in inhibitor patients, to frequently evaluate the efficacy of hemostasis during the course of a bleeding event, and to switch products early if the response to treatment is unsatisfactory. (C) 2008 Elsevier Ltd. All rights reserved.}},
  author       = {{Gomperts, Edward D. and Astermark, Jan and Gringeri, Alessandro and Teitel, Jerome}},
  issn         = {{1532-1681}},
  keywords     = {{discordant pairs; hemophilia; inhibitors; FEIBA; NovoSeven}},
  language     = {{eng}},
  number       = {{Suppl 1}},
  pages        = {{1--11}},
  publisher    = {{Churchill Livingstone}},
  series       = {{Blood Reviews}},
  title        = {{From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors}},
  url          = {{http://dx.doi.org/10.1016/S0268-960X(08)70001-8}},
  doi          = {{10.1016/S0268-960X(08)70001-8}},
  volume       = {{22}},
  year         = {{2008}},
}